WO2002047730A2 - Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins - Google Patents
Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins Download PDFInfo
- Publication number
- WO2002047730A2 WO2002047730A2 PCT/US2001/051151 US0151151W WO0247730A2 WO 2002047730 A2 WO2002047730 A2 WO 2002047730A2 US 0151151 W US0151151 W US 0151151W WO 0247730 A2 WO0247730 A2 WO 0247730A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- protein
- therapeutic agent
- compound
- nerve
- Prior art date
Links
- 0 C*C(NC(NC1=O)=Nc2c1nc[n]2COCCO)=O Chemical compound C*C(NC(NC1=O)=Nc2c1nc[n]2COCCO)=O 0.000 description 2
- WPOLZDKHOSYGLO-ZVGDGVOWSA-N CC(N/C1=C/C/C=C\C=C/C=C\C=C1)OC Chemical compound CC(N/C1=C/C/C=C\C=C/C=C\C=C1)OC WPOLZDKHOSYGLO-ZVGDGVOWSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Definitions
- the present invention relates to compounds which can be used to selectively deliver moieties to nerve cells. More specifically, the invention relates to compounds which include a therapeutic moiety and facilitate absorption of the therapeutic moiety by nerve cells.
- steroid hormone cortisone and its derivatives are widely used to treat inflammation in the body including the nerve system to reduce symptoms such as swelling, tenderness and pain.
- the steroid dosage has to be kept at the lowest effective level because of its severe side effects.
- Steroid hormone binds to its cognate nuclear hormone receptor and induces a cascade of cellular effects, including programmed cell death of the neurons in the brain (Kawata M., et al., J. Steroid Biochem. Mol. Biol. 65: 273-280 (1998)).
- steroid hormone receptors such as glucocorticord receptor for cortisone
- distribute in a wide variety of tissues and cells nonspecific interactions of the hormone with its cognate receptor in different sites is unavoidable if the drug is circulated systemically.
- liposomes have been used as carrier molecules to deliver a broad spectrum of agents including small molecules, DNAs, RNAs, and proteins.
- Liposome mediated delivery of pharmaceutical agents has major drawbacks because of its lack of target specificity. Attempts have been made to overcome this problem by covalently attaching whole site-specific antibody or Fab fragments to liposomes containing a pharmaceutical agent (Martin et al., Biochem. 20, 4229- 4238, (1981)).
- B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell;
- M is a moiety which performs a useful non-cytotoxic function when absorbed by a nerve cell; and L is a linker coupling B to M.
- the compounds have the general formula:
- B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell;
- TM is a therapeutic moiety which has a non-cytotoxic therapeutic effect when absorbed by a nen/e cell
- L is a linker coupling B to TM.
- the compounds have the general formula:
- B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell;
- IM is a non-cytotoxic imaging moiety which can be used to image a nerve cell or an intracellular component of the nerve cell; and L is a linker coupling B to IM.
- binding agents B which may be used include, but are not limited to, nucleic acid sequences, peptides, peptidomimetics, antibodies and antibody fragments.
- nucleic acids that can serve as the binding agent B include, but are not limited to, DNA and RNA ligands that function as antagonists of nerve growth factors or inhibit binding of other growth factors to nerve cell surface receptors.
- peptides that can serve as the binding agent B include, but are not limited to, members of the ne ⁇ /e growth factors (neurotrophin) family such as NGF, BDNF, NT-3, NT-4, NT-6; derivatives, analogs, and fragments of nerve growth factors such as recombinant molecules of NGF and BDNF; and synthetic peptides that bind to nerve ceil surface receptors and have agonist or antagonist activities of nerve growth factors.
- neurotrophin neurotrophin
- Antibodies, derivatives of antibodies and antibody fragments can also serve as the binding agent B.
- binding agent B examples include, but are not limited to, anti-human trkA monoclonal antibody 5C3 and anti-human p75 monoclonal antibody MC192.
- the therapeutic moiety TM is selected to perform a non-cytotoxic therapeutic function within nerve cells.
- non-cytotoxic functions which the therapeutic moiety TM may perform include, but are not limited to, the functions performed by adrenergic agents, adrenergic agonists, analgesics, anti-trauma agents, anti-viral agents, gene therapy agents, and hormones (growth factors, interferons, etc.).
- classes of therapeutic moieties include, but are not limited to, adrenergic agents (e.g., epinephrine, norepinephrine, dopamine, etenolol), adrenergic agonists (e.g., phenylephrine, isoproterenol, and noradrenaline), analgesics (e.g., opioids, codeine, oxycodone), anti- trauma agents, anti-viral agents (e.g., acyclovir, gancyclovir, AZT, ddl, ddC, etc.), gene therapy agents (e.g., DNAs or RNAs which introduce a gene or replace a mutated gene), steroids (e.g., cortisone, progesterone, estrogen), and hormones (e.g., growth factors, interferons).
- adrenergic agents e.g., epinephrine, norepinep
- the therapeutic moiety TM is a charged moiety.
- Cells have difficulty transporting charged molecules across cell membranes.
- the binding agent B serves to facilitate transport of a charged therapeutic moiety TM into a cell.
- the compound i.e. the conjugate formed between B and TM
- the compound is metabolized to form a metabolite product that comprises the charged therapeutic moiety TM.
- the metabolite product is less prone to being transported across the cell membrane out of the cell relative to the conjugate because of the metabolism of the conjugate resulting in the separation of the therapeutic moeity TM from the binding agent B.
- the metabolite product is also less prone to being transported across the cell membrane out of the cell relative to a non-charged version of the therapeutic moiety due to the charge which the therapeutic moiety carries.
- compounds which comprise a charged derivative of a therapeutic agent having a therapeutic activity, the charged derivative being conjugated to a protein having a biological activity of being transported across a cell membrane into a cell, the cell metabolizing at least a portion of the protein to form a charged metabolite product that possesses the therapeutic activity of the therapeutic agent, the charged metabolite product being less prone to being transported across the cell membrane out of the cell relative to the conjugate and less prone to being transported across the cell membrane out of the cell relative to the therapeutic agent.
- the charged therapeutic moiety TM is a quartinery alkyl amine derivative of a therapeutic moiety
- a particular example of a quartinery alkyl amine derivative of a therapeutic moiety TM is a quartinery alkyl amine of propoxycaine, shown in Table 3.
- the imaging moiety IM is a non-cytotoxic agent which can be used to locate and optionally visualize a nerve cell or an internal component of the nerve cell which has absorbed the imaging moiety. Fluorescent dyes may be used as an imaging moiety IM. Radioactive agents which are non-cytotoxic may also be an imaging moiety IM.
- the linker may be any moiety which can be used to link the binding agent B to the moiety M.
- the linker is a cleavable linker.
- a cleavable linker enables the moiety M linked to the binding agent B to be released from the compound once absorbed by the nerve cell.
- the cleavable linker may be cleaved by a chemical agent, enzymatically, due to a pH change, or by being exposed to energy. Examples of forms of energy which may be used include light, microwave, ultrasound, and radiofrequency.
- the present invention also relates to a method for selectively delivering a moiety into ne ⁇ /e cells comprising the steps of: delivering to a patient a compound having the general formula:
- B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell
- M is a moiety which performs a useful non-cytotoxic function when absorbed by a nerve cell
- moiety M is a therapeutic moiety TM as described herein and in another embodiment is an imaging moiety IM. The above method can be used to deliver therapeutic moieties for treating a variety of neurological disorders when the therapeutic moiety TM is a moiety useful for treating such neurological disorders.
- the above method can be used to deliver therapeutic moieties for treating pain when a therapeutic moiety TM for treating pain, such as an analgesic, is included as the therapeutic moiety TM in the compound.
- the above method can also be used to deliver steroid hormones for treating nerve damage when a therapeutic moiety TM for treating nerve damage, such as a steroid hormone, is included as the therapeutic moiety TM in the compound.
- the above method can also be used to stimulate ne ⁇ /e growth when a therapeutic moiety TM for inducing the production of a nerve growth factor is included as the therapeutic moiety TM in the compound.
- the above method can also be used to treat infected nerve cells infected with viruses or immunize nerve cells from viruses when the therapeutic moiety TM in the compound is an antiviral agent.
- the above method can also be used to perform gene therapy when the therapeutic moiety TM is a gene therapy agent.
- the present invention also relates to a method for improving intracellular administration of a therapeutic agent.
- the method comprises contacting cells with a compound comprising a charged derivative of a therapeutic agent having a therapeutic activity, the charged derivative being conjugated to a protein having a biological activity of being transported across a cell membrane into a cell; and having the cell transport the compound into the cell where the cell metabolizes at least a portion of the protein to form a charged metabolite product that possesses the therapeutic activity of the therapeutic agent, the charged metabolite product being less prone to being transported across the cell membrane out of the cell relative to the conjugate and less prone to being transported across the cell membrane out of the cell relative to the therapeutic agent.
- this method is used in conjunction with the conjugates of the present invention and hence is used in conjunction with the methods of the present invention for selectively delivering a moiety into nerve cells.
- the charged therapeutic moiety TM is a quartinery alkyl amine derivative of a therapeutic moiety
- a particular example of a quartinery alkyl amine derivative of a therapeutic moiety TM is a quartinery alkyl amine of propoxycaine, shown in Table 3.
- the present invention relates to compounds which include a binding agent which binds to a nerve cell surface receptor and facilitates absorption of the compound by the nerve cell; and a moiety.
- Different Moieties may be included in the compounds of the present invention including therapeutic moieties that are non-cytotoxic to the nerve cells and imaging moieties which can be used to image ne ⁇ /e cells which absorb these compounds.
- compounds of the present invention have the general formula: B-L-TM
- B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell;
- TM is a therapeutic moiety which has a non-cytotoxic therapeutic effect when absorbed by a ne ⁇ /e cell; and L is a linker coupling B to TM.
- the binding agent B serves as a homing agent for nerve cells by selectively binding to nerve cell surface receptors.
- the binding agent B also serves to facilitate absorption of the compound by the nerve cell.
- the binding agent B can be any molecule which can perform these two functions.
- Particular classes of binding agents which may be used include, but are not limited to, nucleic acid sequences, peptides, peptidomimetics, antibodies and antibody fragments.
- nucleic acids that can serve as the binding agent B include, but are not limited to, DNA and RNA ligands that function as antagonists of nerve growth factors or inhibit binding of other growth factors to nerve cell surface receptors (Binkley, J., et al., Nucleic Acid Res. 23: 3198-3205 (1995); Jellinek, D., et al., Biochem. 33:10450- 10456 (1994)).
- peptides that can serve as the binding agent B include, but are not limited to, members of the nerve growth factors (neurotrophin) family such as NGF, BDNF, NT-3, NT-4, NT-6, etc. (see reviews: Frade, J.
- antibodies, derivatives of antibodies and antibody fragments that can serve as the binding agent B include, but are not limited to, anti-human trkA monoclonal antibody 5C3 (Kramer, K., et al., Eur. J. Cancer 33: 2020-2091 (1997)), anti-human p75 monoclonal antibody MC192 (Maliatchouk, S. and Saragovi, H. U., J. Neurosci. 17: 6031-7).
- the therapeutic moiety TM is selected to perform a non-cytotoxic therapeutic function within nerve cells.
- non-cytotoxic functions which the therapeutic moiety TM may perform include, but are not limited to, the functions performed by analgesics, anti-trauma agents, anti-viral agents, gene therapy agents, and hormones (growth factors, interferons, etc.).
- classes of therapeutic moieties include, but are not limited to, adrenergic agents (e.g., epinephrine, norepinephrine, dopamine, etenolol), adrenergic agonists (e.g., phenylephrine, isoproterenol, and noradrenaline), analgesics (e.g., opioids, codeine, oxycodone), anti- trauma agents, anti-viral agents (e.g., acyclovir, gancyclovir, AZT, ddl, ddC, etc.), gene therapy agents (e.g., DNAs or RNAs which introduce a gene or replace a mutated gene), steroids (e.g., cortisone, progesterone, estrogen), and hormones (e.g., growth factors, interferons).
- adrenergic agents e.g., epinephrine, norepinep
- the linker L serves to link the binding agent B to the therapeutic moiety TM.
- linkers are known in the art for linking two molecules together, particularly, for linking a moiety to a peptide or nucleic acid, all of which are included within the scope of the present invention.
- linkers examples include amide, alkylamine, thiolether, alkyl, cycloalkyl, aryl linkages such as those described in Hermanson, G.T., Bioconjugate Techniques (1996), Academic Press, San Diego, CA.
- the linker L is a cleavable linker. This enables the therapeutic moiety TM to be released from the compound once absorbed by the nerve cell. This may be desirable when the therapeutic moiety TM has a greater therapeutic effect when separated from the binding agent.
- the therapeutic moiety TM may have a better ability to be absorbed by an intracellular component of the nerve cell when separated from the binding agent. Accordingly, it may be necessary or desirable to separate the therapeutic moiety TM from the compound so that the therapeutic moiety TM can enter the intracellular compartment.
- Cleavage of the linker releasing the therapeutic moiety may be as a result of a change in conditions within the nerve cells as compared to outside the nerve cells, for example, due to a change in pH within the nerve cell. Cleavage of the linker may occur due to the presence of an enzyme within the nerve cell which cleaves the linker once the compound enters the nerve cell. Alternatively, cleavage of the linker may occur in response to energy or a chemical being applied to the nerve cell. Examples of types of energies that may be used to effect cleavage of the linker include, but are not limited to light, ultrasound, microwave and radiofrequency energy.
- the linker L used to link the binding agent B to the therapeutic moiety TM may be a photolabile linker.
- photolabile linkers examples include those linkers described in US Patent No. 5,767,288 and No. 4,469,774.
- the linker L used to link the binding agent B to the therapeutic moiety TM may also be an acid labile linker.
- acid labile linkers include linkers formed by using cis-aconitic acid, cis- carboxylic alkatriene, polymaleic anhydride, and other acidlabile linkers, such as those linkers described in US Patent Nos. 5,563,250 and 5,505, 931.
- Further examples of cleavable linkers include, but are not limited to the linkers described in Lin, et al., J. Org. Chem. 56:6850-6856 (1991); Ph.D.
- B is a binding agent capable of selectively binding to a nerve cell surface receptor and mediating absorption of the compound by the nerve cell;
- IM is a non-cytotoxic imaging moiety which can be used to image the nerve cell or an intracellular component of the nerve cell; and L is a linker coupling B to IM.
- the binding agent B and linker L may be varied as described above with regard to compounds having the general formula B-L-TM.
- the imaging moiety IM may be a non-cytotoxic moiety which can be used to image nerve cells. Examples of imaging moieties that may be used include fluorescent dyes and radioisotopes which are non-cytotoxic.
- the present invention also relates to a method for selectively delivering a non-cytotoxic therapeutic moiety into nerve cells comprising the steps of: delivering to a patient a therapeutic amount of a compound having the general formula:
- B is a binding agent capable of selectively binding to a ne ⁇ te cell surface receptor and mediating absorption of the compound by the nerve cell
- TM is a therapeutic moiety which has a non- cytotoxic therapeutic effect when absorbed by a nerve cell
- L is a linker coupling B to TM; having the compound selectively bind to a nerve cell surface receptor via the binding agent B; and having the compound be absorbed by the nerve cell mediated by the binding of the binding agent B to the nerve cell surface receptor.
- the method of the present invention offers the advantage of specifically targeting a non-cytotoxic therapeutic moiety to nerve cells where the therapeutic moiety is absorbed by the nerve cells.
- the method utilizes the fact that intemalization of the conjugated agent is mediated by the binding of the binding agent B to nerve cell surface receptors. Once internalized, the therapeutic moiety can accumulate within the nerve cells where it has a therapeutic effect.
- the ability to selectively deliver the compound to ne ⁇ /e cells reduces the overall amount of therapeutic moiety which needs to be administered.
- the method of the present invention can be used to deliver therapeutic moieties for treating a variety of neurological disorders including, but not limited to, Alzheimer's disease, Parkinson's disease, multiple sclerosis, neurodegenerative disease, epilepsy, seizure, migraine, trauma and pain.
- neuropharmaceuticals examples include proteins, antibiotics, adrenergic agents, adrenergic agonists, anticonvulsants, nucleotide analogs, anti-trauma agents, peptides and other classes of agents used to treat or prevent a neurological disorders.
- analgesics such as opioids, codeine and oxycodone can be conjugated to the binding agent B and specifically delivered to the nerve cells. Since the same level of pain relief can be achieved using a smaller dosage of analgesics, side effects such as respiratory depression or potential drug addiction can be avoided or at least ameliorated.
- Steroid hormones such as corticosteriods can also be conjugated with nerve cell-specific binding agents and used to treat inflammation of the nerves, which may reduce the side effects associated with high doses of steroids, such as weight gain, redistribution of fat, increase in susceptibility to infection, and avascular necrosis of bone.
- the method according to the present invention can also be used to deliver agents that induce the production of nerve growth factor in the target nerve cells, especially under conditions of pathogenic under- expression of NGFs (See Riaz, S. S. and Tomlinson, D. R. Prog. Neurobiol. 49: 125-143 (1996)).
- NGF induction has been demonstrated in a wide variety of cell types, such as fibroblasts (Furukawa, Y. et al., FEBS Lett. 247: 463-467(1989)), astrocytes (Furukawa, Y. et al., FEBS Lett. 208: 258-262 (1986)), Schwann cells (Ohi, T. et al., Biochem. Int.
- agents including cytokines, steriods, vitamins, hormones, and unidentified components of serum.
- agents known to induce NGF include 4-methylcatechol, clenbuterol, isoprenaline, L-tryptophan, 1 ,25-dihydroxyvitamin D3, forskolin, fellutamide A, gangliosides and quinone derivatives (Riaz, S. S. and Tomlinson, D. R. Prog. Neurobiol. 49: 125-143 (1996)).
- the method according to the present invention can also be used to deliver antiviral drugs into ne ⁇ te cells in order to treat diseases caused by viral infection, to eliminate viruses spread to the nerves, and to inhibit infection by such viruses.
- viruses that infect the nervous system include but are not limited to rabies viruses, herpes viruses, polioviruses, arboviruses, reoviruses, pseudorabies, corona viruses, and Borna disease viruses.
- antiviral drugs such as acyclovir, gancyclovir, and Cifodovir can be conjugated to the binding agent and used to inhibit active or latent herpes simplex viruses in the peripheral and central nervous system. Specific delivery of the conjugate containing these antiviral drugs to the nervous system can reduce the side effects associated with high doses or long-term administration of these drugs, such as headaches, rash and paresthesia.
- the method according to the present invention can also be used to deliver marker compounds to image intracellular components of the nerve cells.
- marker compounds include but are not limited to fluorescent dyes, radioactive complexes, and other luminophores.
- the method according to the present invention can also be used to perform gene therapy wherein nucleic acids (DNA or RNA) are delivered to the nerve cells. These nucleic acids may serve to replace genes which are either defective, absent or otherwise not properly expressed by the patient's nerve cell genome.
- a compound with a binding agent B is used to selectively deliver the conjugated therapeutic moieties TM to nerve cells.
- the binding agent B interacts with a receptor on the nerve cell and is absorbed by the nerve cell mediated by this interaction. Any molecules possessing these two physical properties are intended to fall within the scope of a binding agent B as it is used in the present invention.
- peptides or proteins with these features can serve as a binding agent B, examples including but not limited to nerve growth factors (neurotrophins), antibodies against nerve cell-specific surface proteins, mutants and synthetic peptides derived from these peptides or proteins.
- neurotrophins are preferably used as the binding agent B.
- Neurotrophins are a family of small, basic polypeptides that are required for the growth, development and survival of neurons. A particular "survival" factor is taken up by the neuron via binding to one or more of a related family of transmembrane receptors. Table I lists several members of the neurotrophin family and their cognate receptors.
- nerve growth factor is the first identified and probably the best characterized member of the neurotrophin family. It has prominent effects on developing sensory and sympathetic neurons of the peripheral nervous system.
- Brain-derived neurotrophic factor (BDNF) has neurotrophic activities similar to NGF, and is expressed mainly in the CNS and has been detected in the heart, lung, skeletal muscle and sciatic nerve in the periphery (Leibrock, J. et al., Nature, 341:149-152 (1989)).
- Neurotrophin-3 (NT-3) is the third member of the NGF family and is expressed predominantly in a subset of pyramidal and granular neurons of the hippocampus, and has been detected in the cerebellum, cerebral cortex and peripheral tissues such as liver and skeletal muscles (Ernfors, P. et al., Neuron 1: 983-996 (1990)).
- Neurotrophin-4 (also called NT-4/5) is the most variable member of the neurotrophin family.
- Neurotrophin-6 (NT-6) was found in teleost fish and binds to p75 receptor.
- trk and p75 transmembrane glycoproteins
- the trk receptors tyrosine kinase- containing receptor
- p75 receptors possess lower affinity to neurotrophins.
- the receptor-bound NGF is internalized with membrane-bound vesicles and retrogradely transported the neuronal cell body.
- native neurotropins may serve as the binding agent B in the compound according the present invention to deliver the conjugated therapeutic agent TM to the neuronal cell body.
- Table 1 The Neurotrophin Family and Its Receptors.
- mouse NGF has been solved by X-ray crystallography at 2.3 A resolution (McDonald et al., Nature, 345: 411-414, (1991)).
- Murine NGF is a dimeric molecule, with 118 amino acids per protomer.
- the structure of the protomer consists of three antiparallel pairs of beta strands that form a flat surface, four loop regions containing many of the variable residues between different NGF-related molecules, which may determine the different receptor specificities, and a cluster of positively charged side chains, which may provide a complementary interaction with the acidic low-affinity NGF receptor.
- Murine NGF has a tertiary structure based on a cluster of three cysteine disulfides and two extended, but distorted beta-hairpins. One of these ⁇ -hairpin loops was formed by the NGF 29-35 region. Structure/function relationship studies of NGF and NGF-related recombinant molecules demonstrated that mutations in NGF region 25-36, along with other ⁇ -hairpin loop and non- loop regions, significantly influenced NGF/NGF-receptor interactions (Ibanez et al., EMBO J., 10, 2105-2110, (1991)). Small peptides derived from this region have been demonstrated to mimic NGF in binding to trkA receptor and affecting biological responses (LeSêt et al. J. Biol.
- NGF neurotrophin receptors
- BDNF neurotrophin receptor ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇
- antibodies against nerve cell surface receptors that are capable of binding to the receptors and being internalized can also serve as the binding agent B.
- monoclonal antibody (MAb) 5C3 is specific for the NGF docking site of the human p140 trkA receptor, with no cross-reactivity with human trkB receptor.
- MAb 5C3 and its Fab mimic the effects of NGF in vitro, and image human trk-A positive tumors in vivo (Kramer et al., Eur. J. Cancer, 33, 2090-2091, (1997)).
- peptidomimetics that are synthesized by incorporating unnatural amino acids or other organic molecules may serve as the binding agent B of the compound according to the present invention to deliver the conjugated therapeutic agent TM into the nerve cells.
- These synthetic peptide mimics are capable of binding to the nerve cell surface receptor and being internalized into the cell.
- the identification and selection of moieties which can serve as binding agents in the present invention can be readily performed by attaching an imaging moiety IM to the potential binding agent in order to detect whether the potential binding agent is internalized by the nerve cells.
- combinatorial and mutagenesis approaches may be used to identify analogs, derivatives and fragments of known binding moieties which may also be used as ' binding moieties according to the present invention.
- An aspect of the present invention relates to the delivery of compounds into nerve cells which are non-cytotoxic to the nerve cells and perform a therapeutic function.
- therapeutic functions include, but are not limited to, treatment of neurological disorders, gene therapy, intracellular target imaging, cell sorting, or separation schemes.
- classes of therapeutic moieties include, but are not limited to adrenergic agents such as epinephrine, norepinephrine, dopamine, etenolol; adrenergic agonists such as phenylephrine, isoproterenol, and noradrenaline, analgesics such as opioids, codeine, oxycodone; anti- trauma agents; anti-viral agents such as acyclovir, gancyclovir, AZT, ddl, ddC; gene therapy agents such as; steroids such as cortisone, progesterone, estrogen; and hormones such as growth factors and interferons.
- adrenergic agents such as epinephrine, norepinephrine, dopamine, etenolol
- adrenergic agonists such as phenylephrine, isoproterenol, and noradrenaline
- Such compounds may optionally also include an imaging moiety, such as fluorescent moieties, for imaging intracellular components of the nerve cells.
- an imaging moiety such as fluorescent moieties
- a further aspect of the present invention relates to compositions and methods for improving the delivery of a therapeutic agent having a therapeutic activity intracellularly. This is accomplished by using therapeutic moieties which are charged. Cells have difficulty transporting charged molecules across cell membranes.
- the binding agent B serves to facilitate transport of a charged therapeutic moiety TM into a cell.
- the compound i.e. the conjugate formed between B and TM
- the metabolite product is less prone to being transported across the cell membrane out of the cell relative to the conjugate because of the metabolism of the conjugate resulting in the separation of the therapeutic moeity TM from the binding agent B.
- the metabolite product is also less prone to being transported across the cell membrane out of the cell relative to a non-charged version of the therapeutic moiety due to the charge which the therapeutic moiety carries.
- compounds which comprise a charged derivative of a therapeutic agent having a therapeutic activity, the charged derivative being conjugated to a protein having a biological activity of being transported across a cell membrane into a cell, the cell metabolizing at least a portion of the compound to form a charged metabolite product that possesses the therapeutic activity of the therapeutic agent, the charged metabolite product being less prone to being transported across the cell membrane out of the cell relative to the compound and less prone to being transported across the cell membrane out of the cell relative to the therapeutic agent.
- the charged therapeutic moiety TM is a quartinery alkyl amine derivative of a therapeutic moiety.
- a particular example of a quartinery alkyl amine derivative of a therapeutic moiety TM is a quartinery alkyl amine of propoxycaine, shown in Table 3.
- methods comprise administering a therapeutic agent to a patient in a form where the therapeutic agent comprises a charge and is conjugated to a protein having the biological activity of being transported across a cell membrane into a cell.
- the cell metabolizes at least a portion of the compound to form a metabolite product that possesses the therapeutic activity of the therapeutic agent.
- the metabolite product is less prone to being transported across the cell membrane out of the cell relative to the compound because of the metabolism of the compound resulting separation of the therapeutic moiety from the protein, and is less prone to being transported across the cell membrane out of the cell relative to an uncharged version of the therapeutic agent.
- This method may be used in conjunction with the conjugates of the present invention for selectively delivering a moiety to nerve cells.
- charged therapeutic moieties can be used with binding agents that target cells other than nerve cells.
- a binding agent B is linked to a therapeutic moiety TM by a linker L.
- a linker L any method of linking a binding agent to a therapeutic moiety may be used and is intended to fall within the scope of the present invention.
- linkers have been developed for cross linking proteins and conjugating proteins or peptides with other agents. These linkers include zero-length cross linkers, homobifunctional cross- linkers, heterobifunctional cross-linkers and trifunctional cross-linkers. These linkers may have different susceptibility to cleavage under certain conditions. Depending on a particular application according to the present invention, an appropriate linker may be chosen. When an intracellular release of the agent from its conjugate is desired, a cleavable linker is chosen which is susceptible to cleavage by external stimuli such as light and heat, by intracellular enzymes, or by a particular microenvironment inside the cell.
- the linker L has one of the following general structures:
- R.,, R 2 , R 3 , R 4 , R 5 , and R 6 are independently selected from the group consisting of alkyls, aryls, heteroaryls, cycloalkyls, cycloalkenes and heterocycloalkenes.
- One particular embodiment of the present invention relates to compounds which include a cleavable linker L.
- the therapeutic moiety TM is more efficacious or potent when free from a carrier molecule such as a binding agent.
- Many cleavable linker groups have been developed which are susceptible to cleavage and by a wide variety of mechanisms.
- linkers have been developed which may be cleaved by reduction of a disulfide bond, by irradiation of a photolabile bond, by hydrolysis of derivatized amino acid side chain, by serum complement- mediated hydrolysis, and by acid-catalyzed hydrolysis.
- photolabile linkers examples include those linkers described in U.S. Patent Nos. 5,767,288 and No. 4,469,774. Acid-labile linkers are preferred in the practice of the present invention by taking advantage of a cell's receptor-mediated endocytosis pathways. Receptors that are internalized by receptor-mediated endocytosis pass through acidified compartments known as endosomes or receptosomes.
- acid labile linkers which may be used include the cis-aconitic acid, cis-carboxylic alkatriene, polymaleic anhydride, and other acid labile linkers described in US Patent Nos. 5,563,250 and 5,505, 931.
- Table 2 provides several compounds according to the present invention. It is noted that in each instance, the particular therapeutic moieties, binding moieties, and linkers shown may be interchanged with other suitable therapeutic moieties, binding moieties, and linkers. In this regard, the compounds shown in the table are intended to illustrate the diversity of compounds provided according to the present invention. TABLE 2
- B is selected from the group consisting of nerve growth factors NGF, BDNF, NT-3, NT-4, NT-6, anti-neurotrophin receptor antibodies MAb 5C3 and Mab MC192.
- B is selected from the group consisting of nerve growth factors NGF, BDNF, NT-3, NT-4, NT-6, anti-neurotrophin receptor antibodies MAb 5C3 and Mab MC192.
- B is selected from the group consisting of nerve growth factors NGF, BDNF, NT-3, NT-4, NT-6, anti-neurotrophin receptor antibodies MAb 5C3 and Mab MC192.
- B is selected from the group consisting of nerve growth factors NGF, BDNF, NT-3, NT-4, NT-6, anti-neurotrophin receptor antibodies MAb 5C3 and Mab MC192.
- B is selected from the group consisting of nerve growth factors NGF, BDNF,
- Table 3 provides several therapeutic moieties which may be used in the compounds and methods of the present invention for treating pain. It is noted that any of the various binding moieties and linkers described herein may be employed with these therapeutic agents. Indicated in the table below as * are preferred moieties for attaching linkers to the therapeutic moieties.
- Linkers Table 4 provides a series of linkers for linking different therapeutic moieties and binding moieties together. As illustrated, linkers are provided for attaching moieties which have thiol (-SH), hydroxyl (-OH), and amino (-NH2) groups to the linkers. In these examples, neurotrohin is shown as the binding agent. However, it is noted that neurotrohin and these examples are intended to be exemplary only. Other linkers may also be used and are intended as part of the present invention.
- Hydroxyl group conjugations e.g., Steroids, Piroxicam, Acyclovir, Etorphines
- Amino group conjugations e.g., Propoxycaines, Gabapentin, Carbemazepine, Tacrine
- Table 5 lists the amino acid sequences of human neurotrophins (NGF, BDNF, NT-3, and NT-4) that are used as the binding agent (B) of the present invention. Lysine residues that may be used to attach to the linker (L) which in turn is conjugated with the therapeutic moiety (TM) are highlighted and underlined in Table 5.
- NERVE GROWTH FACTOR [SEQ ID NO: 1] :
- BDNF BRAIN DERIVED NEUROTROPHIC FACTOR
- NEUROTROPHIN-3 [SEQ ID NO: 3] :
- NEUROTROPHIN-4 [SEQ ID NO: 4] :
- ARG ARG THR ALA VAL ASP LEU ARG GLY ARG GLU VAL GLU VAL LEU GLY GLU VAL PRO ALA ALA GLY GLY SER PRO LEU
- the compounds of the present invention may be incorporated into a variety of pharmaceutical compositions including, but not limited to: a sterile injectable solution or suspension; hard or soft gelatin capsules; tablets; emulsions; aqueous suspensions, dispersions, and solutions; suppositories.
- Other pharmaceutically suitable formulations for delivering the compounds of the present invention to ne ⁇ te cells may also be used and are intended to fall within the scope of the present invention.
- the compounds according to the present invention can be administered orally, by subcutaneous or other injection, intravenously, intracerebrally, intramuscularly, parenternally, transdermally, nasally or rectally.
- the form in which the compound is administered depends at least in part on the route by which the compound is administered.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002243422A AU2002243422A1 (en) | 2000-11-06 | 2001-11-02 | Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins |
JP2002549299A JP2005503994A (en) | 2000-11-06 | 2001-11-02 | Compounds for intracellular delivery of therapeutic ingredients to nerve cells |
EP01989317A EP1349577A2 (en) | 2000-11-06 | 2001-11-02 | Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins |
CA002436830A CA2436830A1 (en) | 2000-11-06 | 2001-11-02 | Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/707,730 | 2000-11-06 | ||
US09/707,730 US6887861B1 (en) | 1998-12-21 | 2000-11-06 | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2002047730A2 true WO2002047730A2 (en) | 2002-06-20 |
WO2002047730A8 WO2002047730A8 (en) | 2003-02-20 |
WO2002047730A3 WO2002047730A3 (en) | 2003-07-31 |
Family
ID=24842931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/051151 WO2002047730A2 (en) | 2000-11-06 | 2001-11-02 | Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1349577A2 (en) |
JP (1) | JP2005503994A (en) |
AU (1) | AU2002243422A1 (en) |
CA (1) | CA2436830A1 (en) |
WO (1) | WO2002047730A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1345627A1 (en) * | 2000-11-13 | 2003-09-24 | Centre National De La Recherche Scientifique | Targeted modification of intracellular compounds |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5389623A (en) * | 1982-05-18 | 1995-02-14 | University Of Florida | Redox carriers for brain-specific drug delivery |
WO1995007092A1 (en) * | 1993-09-10 | 1995-03-16 | The University Of Medicine And Dentistry Of New Jersey | Blood-brain barrier transporters of neurological agents |
WO1997037966A1 (en) * | 1996-04-09 | 1997-10-16 | Vical Incorporated | Quaternary cytofectins |
WO2000037103A2 (en) * | 1998-12-21 | 2000-06-29 | Xavos | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
WO2001091798A2 (en) * | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
-
2001
- 2001-11-02 JP JP2002549299A patent/JP2005503994A/en active Pending
- 2001-11-02 EP EP01989317A patent/EP1349577A2/en not_active Withdrawn
- 2001-11-02 AU AU2002243422A patent/AU2002243422A1/en not_active Abandoned
- 2001-11-02 WO PCT/US2001/051151 patent/WO2002047730A2/en active Application Filing
- 2001-11-02 CA CA002436830A patent/CA2436830A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5389623A (en) * | 1982-05-18 | 1995-02-14 | University Of Florida | Redox carriers for brain-specific drug delivery |
WO1995007092A1 (en) * | 1993-09-10 | 1995-03-16 | The University Of Medicine And Dentistry Of New Jersey | Blood-brain barrier transporters of neurological agents |
WO1997037966A1 (en) * | 1996-04-09 | 1997-10-16 | Vical Incorporated | Quaternary cytofectins |
WO2000037103A2 (en) * | 1998-12-21 | 2000-06-29 | Xavos | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
WO2001091798A2 (en) * | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1345627A1 (en) * | 2000-11-13 | 2003-09-24 | Centre National De La Recherche Scientifique | Targeted modification of intracellular compounds |
Also Published As
Publication number | Publication date |
---|---|
EP1349577A2 (en) | 2003-10-08 |
JP2005503994A (en) | 2005-02-10 |
WO2002047730A8 (en) | 2003-02-20 |
CA2436830A1 (en) | 2002-06-20 |
AU2002243422A1 (en) | 2002-06-24 |
WO2002047730A3 (en) | 2003-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7718605B2 (en) | Compounds for intracellular delivery of therapeutic moieties to nerve cells | |
US8232251B2 (en) | Compounds for delivery of therapeutic and imaging moieties to nerve cells | |
Yan et al. | Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression | |
DK2360258T3 (en) | Aprotininpolypeptider to transport a compound of blood-brain-barrier | |
US6881829B2 (en) | Chimeric hybrid analgesics | |
US20170080100A1 (en) | Delivery of antibodies to the central nervous system | |
Geisler et al. | Brain neurotensin, psychostimulants, and stress–emphasis on neuroanatomical substrates | |
Friden | Receptor-mediated transport of therapeutics across the blood-brain barrier | |
CN101123978A (en) | Neublastin variants | |
Oh et al. | Overexpression of neurotrophin receptor p75 contributes to the excitotoxin-induced cholinergic neuronal death in rat basal forebrain | |
WO2002047730A2 (en) | Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins | |
AU2002362210B9 (en) | Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon | |
Sheehan et al. | A horseradish peroxidase-light and electron microscopic study of immunoliposomes utilized for intracellular delivery to the rat striatum | |
Patel et al. | Role of Transferrin Receptors In Brain Targeting Delivery | |
Smith | Identification and characterization of the neurotrophic properties of dopamine-releasing protein (DARP) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page |
Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2436830 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002549299 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002243422 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001989317 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001989317 Country of ref document: EP |